NVO:NYSENovo Nordisk A/S Analysis

Novo Nordisk trades at $44.28, comfortably above its 20‑day SMA (43.70) but still below the 200‑day SMA (49.10), indicating a neutral longer‑term trend. The stock’s PE of 10.35 is well under the industry average of 27.16, while the dividend yield of 4.07% offers attractive income. Technicals show a modestly overbought RSI (56) and a bearish MACD histogram, suggesting short‑term pressure near the resistance level of $47.79.
Fundamentally, revenue is growing at 24% with exceptional gross (83%) and operating margins (62%) and a ROE of 71%, but the balance sheet is leveraged (Debt‑to‑Equity 72%) and free cash flow is negative. Recent news highlights rapid uptake of the new Wegovy pill and an upgraded 2026 outlook, underscoring strong demand in the obesity franchise despite lower realized prices. The combination of undervalued multiples, solid earnings, and robust pipeline supports a positive medium‑ to long‑term view, while high volatility (34.9% 30‑day) and beta (~1.55) warrant caution in the near term.